On August 18 Danaher Corporation, based in Washington, D.C., announced the acquisition of Genedata AG for an undisclosed price.
Founded in 1997 and headquartered in Basel, Switzerland, Genedata is at the forefront of transforming data into intelligence for the life sciences industry. Genedata delivers scalable and open solutions that enhance R&D productivity, serving top global biopharmaceutical and biotechnology organizations around the globe.
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. The company designs, manufactures and markets professional, medical, industrial and commercial products and services worldwide. According to its most recent financial report, the company’s revenues for FY 2023 were $23.89 billion.
Genedata’s offerings are expected to add to Danaher’s broad workflow solutions that help accelerate the speed of drug discovery, development, and manufacturing for critical new therapies. Over the past several years Genedata and Danaher have engaged in several successful collaborations.
According to data captured in the LevinPro HC database, this acquisition represents the 159th eHealth transaction of 2024, and the 40th in the medical practice management software specialty.
